Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Oncology
Published in: Clinical and Translational Oncology 7/2013

01-07-2013 | Editorial

Should be NICE have a Spanish NICE?

Authors: J. Feliu, E. Espinosa

Published in: Clinical and Translational Oncology | Issue 7/2013

Login to get access

Excerpt

Cancer is the second leading cause of death in Spain, accounting for 25 % of all deaths. One out of three men and one out of four women will have a cancer during their lives, a proportion that will increase with progressive ageing of the general population. …
Literature
1.
Jönsson B, Wilking N. A global comparison regarding patient access to cancer drugs. Ann Oncol. 2007;18(Suppl 3):1–77.
2.
Sullivan R, Peppercorn J, Sikora K, Zalcberg J, Meropol N, Amir E, et al. Delivering affordable cancer care in high-income countries. Lancet Oncol. 2011;12:933–80.PubMedCrossRef
3.
Elkin EB, Bach PB. Cancer’s next frontier. Addressing high and increasing costs. JAMA. 2010;303:1086–7.PubMedCrossRef
4.
Schrag D. The price tag on progress: chemotherapy for colorectal cancer. N Engl J Med. 2004;351:317–9.PubMedCrossRef
5.
Sánz-Ortiz J. Chemotherapy at the end of life: up until when? Clin Transl Oncol. 2012;14:667–74.PubMedCrossRef
6.
7.
Ocana A, Tannock IF. When are “positive” clinical trials in oncology truly positive? J Natl Cancer Inst. 2011;103:16–20.PubMedCrossRef
8.
European Medicines Agency. Answers from the CHMP Scientific Advisory Group (SAG) for Oncology for revision of the anticancer guideline. EMA/768937/2012.
9.
Pouvourville G. HAS to be NICE. Eur J Health Econ 2013 (in press).
10.
Willemse PHB, Tjan-Heijnen VCG. Difficult decisions in the cost-effectiveness analysis of new cancer treatments. EJHPP. 2009;15:50–3.
11.
Theriault RL. Health care cost: how do we decide value? When do we decide? How do we particularize the decisions? Oncologist. 2012;17:157–9.PubMedCrossRef
12.
Kirkdale R, Krell J, O'Hanlon C, Tuthill M, Waxman J. The cost of a QALY. QJ Med. 2010;103:715–20.CrossRef
13.
Fojo T, Grady C. How much is life worth: cetuximab non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009;101:1044–8.PubMedCrossRef
14.
Murray CJ, Evans DB, Acharya A, Baltussen RM. Development of WHO guidelines on generalized cost-effectiveness analysis. Health Econ. 2000;9:235–51.PubMedCrossRef
15.
Braithwaite RS, Meltzer DO, King JT Jr, Leslie D, Roberts MS. What does the value of modern medicine say about the $50.000 per quality-adjusted life-year decision rule? Med Care. 2008;46:349–56.PubMedCrossRef
Metadata
Title
Should be NICE have a Spanish NICE?
Authors
J. Feliu
E. Espinosa
Publication date
01-07-2013
Publisher
Springer Milan
Published in
Clinical and Translational Oncology / Issue 7/2013
Print ISSN: 1699-048X
Electronic ISSN: 1699-3055
DOI
https://doi.org/10.1007/s12094-013-1051-z

Other articles of this Issue 7/2013

Clinical and Translational Oncology 7/2013 Go to the issue

Research Article

Comparison of second-line treatment outcomes between sensitive and refractory small cell lung cancer patients: a retrospective analysis

Review Article

Optimal management of breakthrough cancer pain (BCP)

Research Article

Increased expression of CD24 is associated with tumor progression and prognosis in patients suffering osteosarcoma

Educational Series - Blue Series

Lung adenocarcinoma in the era of targeted therapies: histological classification, sample prioritization, and predictive biomarkers

Brief Research Article

Lack of Bax expression is associated with irinotecan-based treatment activity in advanced colorectal cancer patients

Educational Series - Red Series

GEICO (Spanish Group for Investigation on Ovarian Cancer) treatment guidelines in ovarian cancer 2012
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits